共 50 条
- [1] PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients[J]. CANCER RESEARCH, 2017, 77Abraham, J. E.Vallier, A-LQian, W.Grybowicz, L.Thomas, S.Mahmud, S.Harvey, C.McAdam, K.Hughes-Davies, L.Roylance, R.Copson, E.Brown, J.Provenzano, E.Tischkowitzand, M.Earl, H. M.
- [2] PARTNER: randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients[J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 585 - 586Abraham, Jean E.Pinilla, KarrenVallier, Anne-LaureGrybowicz, LouiseQian, WendiThomas, StanlyWeiss, MelanieHarvey, CaronKateb, AngelsMachin, AndreaDemiris, NikolaosWulff, JeromeMcAdam, KarenHughes-Davies, LukeRoberts, AnneRoylance, RebeccaCopson, EllenArmstrong, AnneLevitt, NickyProvenzano, ElenaTischkowitz, MarcMcMurtry, EmmaEarl, Helena
- [3] PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients[J]. CANCER RESEARCH, 2019, 79 (04)Abraham, J.Vallier, A-LQian, W.Machin, A.Grybowicz, L.Thomas, S.Weiss, M.Harvey, C.McAdam, K.Hughes-Davies, L.Roberts, A.Roylance, R.Copson, E.Pinilla, K.Armstrong, A.Provenzano, E.Tischkowitz, M.McMurty, E.Earl, H.
- [4] PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Earl, Helena MargaretVallier, Anne-LaureQian, WendiGrybowicz, LouiseThomas, StanlyMahmud, SabaHarvey, CaronMcAdam, KarenHughes-Davies, LukeRoylance, RebeccaCopson, EllenBrown, JessicaProvenzano, ElenaMcMurtry, EmmaTischkowitz, MarcAbraham, Jean
- [5] PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Abraham, JeanVallier, Anne-LaureQian, WendiMachin, AndreaGrybowicz, LouiseThomas, StanlyHarvey, CaronMcAdam, KarenHughes-Davies, LukeRoylance, RebeccaCopson, EllenProvenzano, ElenaPinilla, KarenMcMurtry, EmmaTischkowitz, MarcEarl, Helena Margaret
- [6] PARTNER randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients[J]. CANCER RESEARCH, 2018, 78 (04)Abraham, JeanVallier, Anne-LaureQian, WendiGrybowicz, LouiseThomas, StanlyMachin, AndreaHarvey, CaronChiu, EdmundMcAdam, KarenHughes-Davies, LukeRoylance, RebeccaCopson, EllenArmstrong, AnneProvenzano, ElenaTischkowitz, MarcMcMurtry, EmmaEarl, Helena
- [7] PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Drewett, LynseyLucey, RebeccaPinilla, Karen AndreaGrybowicz, LouiseWulff, JeromeDayimu, AlimuDemiris, NikosVallier, Anne-LaureQian, WendiMachin, AndreaMcAdam, KarenRoylance, RebeccaCopson, EllenArmstrong, Anne C.Levitt, NicolaProvenzano, ElenaTischkowitz, Marc D.McMurtry, EmmaEarl, Helena MargaretAbraham, Jean
- [8] PARTNER: Randomised, phase 2/3 trial evaluating safety & efficacy of adding olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients[J]. BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 45 - 45Abraham, JeanVallier, Anne-LaureQian, WendiMachin, AndreaGrybowicz, LouiseThomas, StanlyWeiss, MelanieHarvey, CaronMcAdam, KarenHughes-Davies, LukeRoberts, AnneRoylance, RebeccaCopson, EllenPinilla, KarenArmstrong, AnneProvenzano, ElenaTischkowitz, MarcMcMurtry, EmmaEarl, Helena
- [9] Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients[J]. CANCER RESEARCH, 2020, 80 (04)Alba, Karen PinillaMcMurtry, EmmaVallier, Anne-LaureGrybowicz, LouiseCopson, EllenArmstrong, AnneRoylance, RebeccaQian, WendiDemiris, NikolaosThomas, StanlyHarvey, CaronHughes-Davies, LukeMcAdam, Karendel Rosario, PaulaHarrop, BryonyProvenzano, ElenaTischkowitz, MarcEarl, Helena M.Abraham, Jean E.
- [10] Efficacy of platinum-based neoadjuvant chemotherapy in early triple-negative breast cancer according to germline BRCA mutation[J]. BREAST, 2023, 68 : S59 - S60Bae, S. J.Jang, J. S.Kook, Y.Baek, S. H.Kim, J. H.Kim, M. J.Lee, S. E.Moon, S.Kim, J. H.Ahn, S. G.Jeong, J.